Lithium chloride combination with rapamycin for the treatment of COVID-19 pneumonia.
Identifieur interne : 000098 ( Main/Exploration ); précédent : 000097; suivant : 000099Lithium chloride combination with rapamycin for the treatment of COVID-19 pneumonia.
Auteurs : Rami Bou Khalil [Liban]Source :
- Medical hypotheses [ 1532-2777 ] ; 2020.
Descripteurs français
- KwdFr :
- Antiviraux (administration et posologie), Association de médicaments (MeSH), Betacoronavirus (effets des médicaments et des substances chimiques), Betacoronavirus (immunologie), Betacoronavirus (physiologie), Chlorure de lithium (administration et posologie), Glycogen synthase kinase 3 beta (antagonistes et inhibiteurs), Humains (MeSH), Infections à coronavirus (immunologie), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (virologie), Modèles biologiques (MeSH), Pandémies (MeSH), Pneumopathie virale (immunologie), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (virologie), Réplication virale (effets des médicaments et des substances chimiques), Sirolimus (administration et posologie), Sérine-thréonine kinases TOR (administration et posologie).
- MESH :
- administration et posologie : Antiviraux, Chlorure de lithium, Sirolimus, Sérine-thréonine kinases TOR.
- antagonistes et inhibiteurs : Glycogen synthase kinase 3 beta.
- effets des médicaments et des substances chimiques : Betacoronavirus, Réplication virale.
- immunologie : Betacoronavirus, Infections à coronavirus, Pneumopathie virale.
- physiologie : Betacoronavirus.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- virologie : Infections à coronavirus, Pneumopathie virale.
- Association de médicaments, Humains, Modèles biologiques, Pandémies.
English descriptors
- KwdEn :
- Antiviral Agents (administration & dosage), Betacoronavirus (drug effects), Betacoronavirus (immunology), Betacoronavirus (physiology), Coronavirus Infections (drug therapy), Coronavirus Infections (immunology), Coronavirus Infections (virology), Drug Therapy, Combination (MeSH), Glycogen Synthase Kinase 3 beta (antagonists & inhibitors), Humans (MeSH), Lithium Chloride (administration & dosage), Models, Biological (MeSH), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (immunology), Pneumonia, Viral (virology), Sirolimus (administration & dosage), TOR Serine-Threonine Kinases (administration & dosage), Virus Replication (drug effects).
- MESH :
- chemical , administration & dosage : Antiviral Agents, Lithium Chloride, Sirolimus, TOR Serine-Threonine Kinases.
- chemical , antagonists & inhibitors : Glycogen Synthase Kinase 3 beta.
- drug effects : Betacoronavirus, Virus Replication.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- immunology : Betacoronavirus, Coronavirus Infections, Pneumonia, Viral.
- physiology : Betacoronavirus.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Drug Therapy, Combination, Humans, Models, Biological, Pandemics.
DOI: 10.1016/j.mehy.2020.109798
PubMed: 32413699
PubMed Central: PMC7252071
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Lithium chloride combination with rapamycin for the treatment of COVID-19 pneumonia.</title><author><name sortKey="Bou Khalil, Rami" sort="Bou Khalil, Rami" uniqKey="Bou Khalil R" first="Rami" last="Bou Khalil">Rami Bou Khalil</name><affiliation wicri:level="1"><nlm:affiliation>Department of psychiatry, Hotel Dieu de France- Beirut- Lebanon, Saint Joseph University, Beirut, Lebanon. Electronic address: rami.boukhalil@usj.edu.lb.</nlm:affiliation><country xml:lang="fr">Liban</country><wicri:regionArea>Department of psychiatry, Hotel Dieu de France- Beirut- Lebanon, Saint Joseph University, Beirut</wicri:regionArea><wicri:noRegion>Beirut</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32413699</idno><idno type="pmid">32413699</idno><idno type="doi">10.1016/j.mehy.2020.109798</idno><idno type="pmc">PMC7252071</idno><idno type="wicri:Area/Main/Corpus">000073</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000073</idno><idno type="wicri:Area/Main/Curation">000073</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000073</idno><idno type="wicri:Area/Main/Exploration">000073</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Lithium chloride combination with rapamycin for the treatment of COVID-19 pneumonia.</title><author><name sortKey="Bou Khalil, Rami" sort="Bou Khalil, Rami" uniqKey="Bou Khalil R" first="Rami" last="Bou Khalil">Rami Bou Khalil</name><affiliation wicri:level="1"><nlm:affiliation>Department of psychiatry, Hotel Dieu de France- Beirut- Lebanon, Saint Joseph University, Beirut, Lebanon. Electronic address: rami.boukhalil@usj.edu.lb.</nlm:affiliation><country xml:lang="fr">Liban</country><wicri:regionArea>Department of psychiatry, Hotel Dieu de France- Beirut- Lebanon, Saint Joseph University, Beirut</wicri:regionArea><wicri:noRegion>Beirut</wicri:noRegion></affiliation></author></analytic><series><title level="j">Medical hypotheses</title><idno type="eISSN">1532-2777</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (administration & dosage)</term><term>Betacoronavirus (drug effects)</term><term>Betacoronavirus (immunology)</term><term>Betacoronavirus (physiology)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (immunology)</term><term>Coronavirus Infections (virology)</term><term>Drug Therapy, Combination (MeSH)</term><term>Glycogen Synthase Kinase 3 beta (antagonists & inhibitors)</term><term>Humans (MeSH)</term><term>Lithium Chloride (administration & dosage)</term><term>Models, Biological (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (immunology)</term><term>Pneumonia, Viral (virology)</term><term>Sirolimus (administration & dosage)</term><term>TOR Serine-Threonine Kinases (administration & dosage)</term><term>Virus Replication (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (administration et posologie)</term><term>Association de médicaments (MeSH)</term><term>Betacoronavirus (effets des médicaments et des substances chimiques)</term><term>Betacoronavirus (immunologie)</term><term>Betacoronavirus (physiologie)</term><term>Chlorure de lithium (administration et posologie)</term><term>Glycogen synthase kinase 3 beta (antagonistes et inhibiteurs)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (immunologie)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (virologie)</term><term>Modèles biologiques (MeSH)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (immunologie)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pneumopathie virale (virologie)</term><term>Réplication virale (effets des médicaments et des substances chimiques)</term><term>Sirolimus (administration et posologie)</term><term>Sérine-thréonine kinases TOR (administration et posologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term><term>Lithium Chloride</term><term>Sirolimus</term><term>TOR Serine-Threonine Kinases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Glycogen Synthase Kinase 3 beta</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiviraux</term><term>Chlorure de lithium</term><term>Sirolimus</term><term>Sérine-thréonine kinases TOR</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Glycogen synthase kinase 3 beta</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Betacoronavirus</term><term>Réplication virale</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Betacoronavirus</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Betacoronavirus</term><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Therapy, Combination</term><term>Humans</term><term>Models, Biological</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Association de médicaments</term><term>Humains</term><term>Modèles biologiques</term><term>Pandémies</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32413699</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2777</ISSN><JournalIssue CitedMedium="Internet"><Volume>142</Volume><PubDate><Year>2020</Year><Month>09</Month></PubDate></JournalIssue><Title>Medical hypotheses</Title><ISOAbbreviation>Med Hypotheses</ISOAbbreviation></Journal><ArticleTitle>Lithium chloride combination with rapamycin for the treatment of COVID-19 pneumonia.</ArticleTitle><Pagination><MedlinePgn>109798</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0306-9877(20)30905-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mehy.2020.109798</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bou Khalil</LastName><ForeName>Rami</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of psychiatry, Hotel Dieu de France- Beirut- Lebanon, Saint Joseph University, Beirut, Lebanon. Electronic address: rami.boukhalil@usj.edu.lb.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Hypotheses</MedlineTA><NlmUniqueID>7505668</NlmUniqueID><ISSNLinking>0306-9877</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber><NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber><NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C000605506">GSK3B protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>G4962QA067</RegistryNumber><NameOfSubstance UI="D018021">Lithium Chloride</NameOfSubstance></Chemical><Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber><NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018021" MajorTopicYN="N">Lithium Chloride</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">Coronavirus</Keyword><Keyword MajorTopicYN="Y">Lithium</Keyword><Keyword MajorTopicYN="Y">Rapamycin</Keyword><Keyword MajorTopicYN="Y">mTOR</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32413699</ArticleId><ArticleId IdType="pii">S0306-9877(20)30905-1</ArticleId><ArticleId IdType="doi">10.1016/j.mehy.2020.109798</ArticleId><ArticleId IdType="pmc">PMC7252071</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Liban</li></country></list><tree><country name="Liban"><noRegion><name sortKey="Bou Khalil, Rami" sort="Bou Khalil, Rami" uniqKey="Bou Khalil R" first="Rami" last="Bou Khalil">Rami Bou Khalil</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000098 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000098 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32413699
|texte= Lithium chloride combination with rapamycin for the treatment of COVID-19 pneumonia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32413699" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |